Astrazeneca says ties up with Moderna to co-develop immuno-oncology mRNA
Tuesday, January 12, 2016
Astrazeneca Plc Co and Moderna Therapeutics announce new collaboration to co-develop and co-commercialise immuno-oncology mRNA Therapeutics.
Two companies will co-commercialise resulting products in US under a 50:50 profit sharing arrangement.
Astrazeneca and Moderna have agreed to collaborate on two specific immuno-oncology programmes.
First-in-human study is expected to commence in late 2016.
Holds exclusive access to select any target of choice in cardiometabolic diseases over a period of up to 5 yrs for subsequent development in mRNA.
Collaboration will combine Medimmune's protein engineering and cancer biology expertise with moderna's mrna platform.
Astrazeneca will lead ex-US commercialisation efforts, with Moderna receiving tiered royalties up to substantial double digits on ex-US sales.
reuters.com
